These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 36724586)
1. Beyond BRCA: Patterns of risk-reducing surgery for non-BRCA, homologous recombination repair pathway gene variant carriers. Lee SS; Karpel HC; Oh C; Smith J; Pothuri B Gynecol Oncol; 2023 Mar; 170():234-240. PubMed ID: 36724586 [TBL] [Abstract][Full Text] [Related]
2. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea. Kim SI; Lim MC; Lee DO; Kong SY; Seo SS; Kang S; Lee ES; Park SY J Cancer Res Clin Oncol; 2016 Jan; 142(1):333-40. PubMed ID: 26438354 [TBL] [Abstract][Full Text] [Related]
3. Patterns of care and outcomes of risk reducing surgery in women with pathogenic variants in non-BRCA and Lynch syndrome ovarian cancer susceptibility genes. Schwartz ZP; Li AJ; Walsh CS; Rimel BJ; Alvarado MM; Lentz SE; Cass I Gynecol Oncol; 2023 Jun; 173():1-7. PubMed ID: 37030072 [TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer. Wei X; Sun L; Slade E; Fierheller CT; Oxley S; Kalra A; Sia J; Sideris M; McCluggage WG; Bromham N; Dworzynski K; Rosenthal AN; Brentnall A; Duffy S; Evans DG; Yang L; Legood R; Manchanda R JAMA Netw Open; 2024 Feb; 7(2):e2355324. PubMed ID: 38334999 [TBL] [Abstract][Full Text] [Related]
5. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers. Lee YJ; Lee SW; Kim KR; Jung KH; Lee JW; Kim YM J Gynecol Oncol; 2017 Jan; 28(1):e3. PubMed ID: 27670257 [TBL] [Abstract][Full Text] [Related]
6. Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated at a large urban comprehensive cancer center. Assad H; Levitin M; Petrucelli N; Manning M; Thompson HS; Chen W; Jang H; Simon MS Breast Cancer Res Treat; 2024 Jul; 206(2):261-272. PubMed ID: 38605155 [TBL] [Abstract][Full Text] [Related]
7. Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers. Lee EG; Kang HJ; Lim MC; Park B; Park SJ; Jung SY; Lee S; Kang HS; Park SY; Park B; Joo J; Han JH; Kong SY; Lee ES Cancer Res Treat; 2019 Jan; 51(1):280-288. PubMed ID: 29747489 [TBL] [Abstract][Full Text] [Related]
8. BRCA Mutation Patients: Are There Other Predisposing Factors for Ovarian Cancer Occurrence? A Multicenter Retrospective Study. Loizzi V; Mongelli M; Arezzo F; Romagno I; Cazzato G; Popescu O; Legge F; Trerotoli P; Silvestris E; Kardhashi A; Cormio G Gynecol Obstet Invest; 2024; 89(2):87-94. PubMed ID: 38246147 [TBL] [Abstract][Full Text] [Related]
9. Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation. Kim D; Kang E; Hwang E; Sun Y; Hwang Y; Yom CK; Kim K; No JH; Kim YB; Kim SW Fam Cancer; 2013 Dec; 12(4):621-8. PubMed ID: 23504064 [TBL] [Abstract][Full Text] [Related]
10. Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer. Straub MM; Podoll MB; David SN; Wiesner GL; Desouki MM Ann Diagn Pathol; 2018 Oct; 36():28-30. PubMed ID: 30055521 [TBL] [Abstract][Full Text] [Related]
11. Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study. Pla-Juher H; Pardo M; Izquierdo ÀJ; Darder E; Carbó A; Munté E; Torres-Esquius S; Balmaña J; Lázaro C; Brunet JM; Barretina-Ginesta MP Clin Transl Oncol; 2024 Apr; 26(4):1033-1037. PubMed ID: 37682500 [TBL] [Abstract][Full Text] [Related]
12. Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study. Grandi G; Sammarini M; Cortesi L; Toss A; Botticelli L; Varliero F; Sighinolfi G; Barbieri E; Facchinetti F Menopause; 2021 Feb; 28(3):263-270. PubMed ID: 33534430 [TBL] [Abstract][Full Text] [Related]
13. Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis. Wang Y; Song Z; Zhang S; Wang X; Li P Eur J Surg Oncol; 2022 Jun; 48(6):1209-1216. PubMed ID: 35216860 [TBL] [Abstract][Full Text] [Related]
14. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions. Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X Front Genet; 2021; 12():674094. PubMed ID: 34917121 [No Abstract] [Full Text] [Related]
15. Impact of the coverage of risk-reducing salpingo-oophorectomy by the national insurance system for women with BRCA pathogenic variants in Japan. Nomura H; Abe A; Fusegi A; Yoshimitsu T; Misaka S; Murakami A; Matsumoto T; Tsumura S; Kanno M; Aoki Y; Netsu S; Omi M; Tanigawa T; Okamoto S; Omatsu K; Yunokawa M; Kanao H; Habano E; Arakawa H; Kaneko K; Ueki A; Haruyama Y; Inari H; Ueno T Sci Rep; 2023 Jan; 13(1):1018. PubMed ID: 36658289 [TBL] [Abstract][Full Text] [Related]
16. Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy? Grandi G; Perrone AM; Perrone A; Mandato VD; Comerci G; Sammarini M; Merisio C; Amadori A; Stefanetti M; Martinello R; Facchinetti F; De Iaco P; Maturitas; 2021 Jan; 143():59-64. PubMed ID: 33308637 [TBL] [Abstract][Full Text] [Related]
17. Uptake Rate of Risk-Reducing Salpingo-Oophorectomy and Surgical Outcomes of Female Germline Lim H; Kim SI; Hyun S; Lee GB; Seol A; Lee M Yonsei Med J; 2021 Dec; 62(12):1090-1097. PubMed ID: 34816639 [TBL] [Abstract][Full Text] [Related]
18. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy. van der Aa JE; Hoogendam JP; Butter ES; Ausems MG; Verheijen RH; Zweemer RP Fam Cancer; 2015 Dec; 14(4):539-44. PubMed ID: 26264902 [TBL] [Abstract][Full Text] [Related]
19. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma. Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148 [TBL] [Abstract][Full Text] [Related]
20. Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing. Cummings S; Roman SS; Saam J; Bernhisel R; Brown K; Lancaster JM; Usha L J Ovarian Res; 2021 Apr; 14(1):61. PubMed ID: 33926482 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]